Mirjam Schunk

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators

Ole Wichmann, Joaquím Gascón, Mirjam Schunk et al. · The Journal of Infectious Diseases · 2007 · 172 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 132 citations · Full text

Veterinary Medicine, Immunology, Molecular Pharmaceutics +17

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

Hannah Kibuuka, Robert Kimutai, Leonard Maboko et al. · The Journal of Infectious Diseases · 2010 · 105 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · medRxiv · 2020 · 103 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17